Telescope Innovations Presents Results of Second Fiscal Quarter 2025
Telescope Innovations Corp (TELIF) reported Q2 2025 financial results with revenues of $1.0 million, up from $686,205 in Q2 2024, and an adjusted EBITA loss of $441,837. Expenses increased to $1.7 million from $1.3 million year-over-year.
Key operational highlights include: expansion of DirectInject-LC™ product into China through Mettler Toledo partnership; development of EasyFrit sampling filter accessory; 33% team growth supporting Self-Driving Lab development with Pfizer; successful production of >99% pure battery-grade lithium carbonate using ReCRFT™ technology; and CTO Jason Hein receiving the 2025 R.U. Lemieux Award.
The company continues to reinvest revenues for operational growth, with results aligning with management's FY 2025 targets.
Telescope Innovations Corp (TELIF) ha riportato i risultati finanziari del secondo trimestre 2025 con ricavi di 1,0 milioni di dollari, in aumento rispetto ai 686.205 dollari del secondo trimestre 2024, e una perdita EBITA rettificata di 441.837 dollari. Le spese sono aumentate a 1,7 milioni di dollari rispetto a 1,3 milioni anno su anno.
I principali risultati operativi includono: l'espansione del prodotto DirectInject-LC™ in Cina tramite la partnership con Mettler Toledo; lo sviluppo dell'accessorio filtro di campionamento EasyFrit; una crescita del team del 33% a supporto dello sviluppo del Self-Driving Lab con Pfizer; la produzione con successo di carbonato di litio di qualità batteria con purezza superiore al 99% utilizzando la tecnologia ReCRFT™; e il CTO Jason Hein che ha ricevuto il premio R.U. Lemieux 2025.
L'azienda continua a reinvestire i ricavi per la crescita operativa, con risultati in linea con gli obiettivi di gestione per l'anno fiscale 2025.
Telescope Innovations Corp (TELIF) informó los resultados financieros del segundo trimestre de 2025 con ingresos de 1,0 millones de dólares, un aumento respecto a los 686.205 dólares del segundo trimestre de 2024, y una pérdida EBITA ajustada de 441.837 dólares. Los gastos aumentaron a 1,7 millones desde 1,3 millones año tras año.
Los aspectos operativos clave incluyen: la expansión del producto DirectInject-LC™ en China a través de la asociación con Mettler Toledo; el desarrollo del accesorio de filtro de muestreo EasyFrit; un crecimiento del equipo del 33% apoyando el desarrollo del Self-Driving Lab con Pfizer; la producción exitosa de carbonato de litio grado batería con pureza superior al 99% usando la tecnología ReCRFT™; y el CTO Jason Hein recibiendo el premio R.U. Lemieux 2025.
La compañía continúa reinvirtiendo los ingresos para el crecimiento operativo, con resultados alineados con los objetivos de la dirección para el año fiscal 2025.
Telescope Innovations Corp (TELIF)는 2025년 2분기 재무 실적을 발표했으며, 매출은 100만 달러로 2024년 2분기의 686,205달러에서 증가했고, 조정 EBITA 손실은 441,837달러를 기록했습니다. 비용은 전년 동기 대비 130만 달러에서 170만 달러로 증가했습니다.
주요 운영 성과로는 Mettler Toledo와의 파트너십을 통한 DirectInject-LC™ 제품의 중국 시장 확장; EasyFrit 샘플링 필터 액세서리 개발; Pfizer와 함께하는 Self-Driving Lab 개발 지원을 위한 팀 33% 성장; ReCRFT™ 기술을 이용한 99% 이상의 순도 배터리 등급 탄산리튬 성공적 생산; 그리고 CTO Jason Hein이 2025년 R.U. Lemieux 상을 수상한 점이 포함됩니다.
회사는 운영 성장을 위해 매출을 지속적으로 재투자하고 있으며, 결과는 2025 회계연도 경영 목표와 부합합니다.
Telescope Innovations Corp (TELIF) a publié ses résultats financiers du deuxième trimestre 2025 avec un chiffre d'affaires de 1,0 million de dollars, en hausse par rapport à 686 205 dollars au deuxième trimestre 2024, et une perte EBITA ajustée de 441 837 dollars. Les dépenses ont augmenté à 1,7 million de dollars contre 1,3 million d'une année sur l'autre.
Les principaux faits marquants opérationnels incluent : l'expansion du produit DirectInject-LC™ en Chine grâce au partenariat avec Mettler Toledo ; le développement de l'accessoire filtre d'échantillonnage EasyFrit ; une croissance de l'équipe de 33 % soutenant le développement du Self-Driving Lab avec Pfizer ; la production réussie de carbonate de lithium de qualité batterie à plus de 99 % de pureté grâce à la technologie ReCRFT™ ; et le CTO Jason Hein recevant le prix R.U. Lemieux 2025.
L'entreprise continue de réinvestir ses revenus pour soutenir sa croissance opérationnelle, avec des résultats conformes aux objectifs de gestion pour l'exercice 2025.
Telescope Innovations Corp (TELIF) meldete die Finanzergebnisse für das zweite Quartal 2025 mit Einnahmen von 1,0 Million US-Dollar, gegenüber 686.205 US-Dollar im zweiten Quartal 2024, und einem bereinigten EBITA-Verlust von 441.837 US-Dollar. Die Ausgaben stiegen im Jahresvergleich von 1,3 Millionen auf 1,7 Millionen US-Dollar.
Wesentliche operative Highlights umfassen: die Expansion des DirectInject-LC™ Produkts nach China durch die Partnerschaft mit Mettler Toledo; die Entwicklung des EasyFrit Probenfilters; ein Teamwachstum von 33 % zur Unterstützung der Entwicklung des Self-Driving Lab mit Pfizer; die erfolgreiche Produktion von >99 % reinem batterietauglichem Lithiumcarbonat mittels ReCRFT™ Technologie; sowie die Auszeichnung des CTO Jason Hein mit dem R.U. Lemieux Award 2025.
Das Unternehmen reinvestiert weiterhin die Einnahmen in das operative Wachstum, wobei die Ergebnisse mit den Managementzielen für das Geschäftsjahr 2025 übereinstimmen.
- Revenue growth of 46% YoY to $1.0 million
- Successful expansion into Chinese market with DirectInject-LC™
- 33% team expansion to support Self-Driving Lab development
- Achievement of >99% pure battery-grade lithium carbonate production
- Adjusted EBITA loss increased to $441,837 from $325,488 YoY
- Expenses increased 34.4% to $1.7 million
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company") a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal quarter ended February 28, 2025 (Q2). The Company generated revenues of
FINANCIAL HIGHLIGHTS OF THE FISCAL QUARTER ENDED FEBRUARY 28, 2025
All values are represented in CAD.
- Revenues of
$1,004,121 (versus$686,205 for the comparable period in FY 2024) - Expenses of
$1,717,470 (versus$1,277,418 for the comparable period in FY 2024) - Adjusted EBITA loss of
$441,837 (versus loss of$325,488 for the comparable period in FY 2024)
OPERATIONAL HIGHLIGHTS
- FLAGSHIP PRODUCT EXPANSION INTO CHINA, AND FIRST USER FORUM HOSTED BY METTLER TOLEDO. Telescope and their global distribution partner, Mettler Toledo, launched the distribution of Telescope's DirectInject-LC™ product in China. The Company also executed several product demonstrations at large accounts in expanded geographic markets, to cadvance the commercial adoption already established in the US, Europe, and Japan. In addition, Mettler Toledo hosted the first DirectInject-LC™ user forum to capitalize on and expand the product's momentum. This seminar was attended by over 200 prospective and active customers, and featured speakers from AstraZeneca, Genentech, and Takeda. These speakers presented the advantages of deploying DirectInject-LC™ within their R&D pipeline, while Telescope also presented the product's features and best practices to expand customer awareness and skill.
- PUBLICATION ON ACCESSORY PRODUCT TO DIRECTINJECT-LC. A new White Paper released by Mettler Toledo with Telescope CTO, Jason Hein, as a co-author, highlights the co-development of a sampling filter accessory to DirectInject-LC™ product, named the EasyFrit. This add-on enhances process understanding for crystallization chemistry and other heterogeneous processes, broadening the platform portfolio and application scope of Telescope's instrument, and thereby enhancing the market appeal of DirectInject-LC™. EasyFrit commercialization is also another example of Telescope's technology leadership and ability to develop advanced analytical tools that are readily deployed in the marketplace
- TEAM GROWTH BY
33% AND PROGRESS ON COLLABORATION WITH PFIZER FOR SELF-DRIVING LAB ("SDL") DEVELOPMENT. The combination of a close collaboration with Pfizer scientists and a strong financial contribution has enabled excellent progress on this project. Telescope's SDL uses artificial intelligence, advanced process analytical technology, and robotic automation to autonomously perform chemistry research. SDLs can optimize material properties and chemical synthesis methods up to 100x faster than traditional research methods, reducing the time and cost of developing new pharmaceuticals. To support the SDL Project, Telescope has expanded its team by33% over the past six months, strengthening its expertise in chemistry, chemical engineering, robotics, and AI-driven automation. This growth supports the Company's ability to scale SDL platforms and meet the rising demand for automated research solutions in high-value chemical and pharmaceutical industries.
- SUCCESSFUL OUTCOME OF BRINE-TO-BATTERY PROGRAM FOR PRODUCTION OF >
99% PURE BATTERY RAW MATERIALS. Over the past year, Telescope Innovations' proprietary ReCRFT™ recrystallization technology has produced battery-grade (>99% pure) lithium carbonate from a wide variety of North American lithium-containing brines. Direct Lithium Extraction (DLE) eluates were obtained from various producers with lithium brine projects across Canada and the US, including potential suppliers and customers for the eventual commercialization of the ReCRFT™ process. ReCRFT™ collapses the lithium carbonate refining flow sheet, reducing these costs to enable a sustainable, on-shore supply of battery raw materials.
- CTO HONOURED WITH 2025 R.U LEMIEUX AWARD. Founder and Chief Technology Officer, Professor Jason Hein, has been granted the prestigious 2025 R.U. Lemieux Award by the Chemical Institute of Canada. This award recognizes Professor Hein's contributions to organic chemistry and his pioneering research into reaction mechanisms and process development. His recognition with the R.U. Lemieux Award is a testament to his impact on both academic and industrial chemistry. Dr. Hein continues to lead Telescope's technology development team to enhance advanced analytics, robotics, and artificial intelligence platforms for process chemistry.
"This quarter's results reflect disciplined execution of our strategy and the strength of our partnerships," commented Henry Dubina, Telescope CEO. "By advancing our enabling technologies and deepening our industry presence, we're building lasting value in markets where innovation drives demand."
Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the fiscal year ended February 28, 2025, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).
About Telescope
Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: hdubina@telescopeinn.com
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/249639
FAQ
What were Telescope Innovations (TELIF) Q2 2025 revenue and earnings?
How much did Telescope Innovations (TELIF) grow its revenue compared to Q2 2024?
What major market expansion did TELIF achieve in Q2 2025?
What is the purity level achieved by TELIF's ReCRFT™ technology for battery materials?
How much did Telescope Innovations expand its team for the SDL Project?
